PHAXIAM Therapeutics Valuation

Is PHXMP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHXMP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PHXMP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PHXMP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHXMP?

Key metric: As PHXMP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PHXMP. This is calculated by dividing PHXMP's market cap by their current revenue.
What is PHXMP's PS Ratio?
PS Ratio	12.7x
Sales	€1.33m
Market Cap	€16.79m

PHXMP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	14.8x
Enterprise Value/EBITDA	-1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PHXMP's PS Ratio compare to its peers?

The above table shows the PS ratio for PHXMP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.9x
PBX ProBiotix Health	5x	n/a	UK£10.7m
VRCI Verici Dx	2.4x	78.8%	UK£8.2m
GENF Genflow Biosciences	10.1x	n/a	UK£6.1m
ONC Oncimmune Holdings	14.1x	105.1%	UK£17.2m
PHXMP PHAXIAM Therapeutics	12.7x	-23.3%	€16.8m

Price-To-Sales vs Peers: PHXMP is expensive based on its Price-To-Sales Ratio (12.7x) compared to the peer average (11.3x).

Price to Sales Ratio vs Industry

How does PHXMP's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.7x	3.5%	US$1.39b
OXB Oxford Biomedica	4.6x	21.0%	US$561.36m
TRX Tissue Regenix Group	1.6x	15.1%	US$50.96m
VRCI Verici Dx	2.4x	78.8%	US$10.27m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: PHXMP is expensive based on its Price-To-Sales Ratio (12.7x) compared to the European Biotechs industry average (8.8x).

Price to Sales Ratio vs Fair Ratio

What is PHXMP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHXMP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	12.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PHXMP's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

4.3%

-21.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

1.3%

13.6%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$745.13

-2.1%

-6.5%